Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models

Loss of bone is a common medical problem and, while it can be treated with available therapies, some of these therapies have critical side effects. We have previously demonstrated that CGS21680, a selective A(2A) adenosine receptor agonist, prevents bone loss, but its on-target toxicities (hypotensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Larrañaga-Vera, Ane, Toti, Kiran S., Flatow, James S., Haraczy, Alexandra J., Warnick, Eugene, Rao, Harsha, Gao, Zhan-Guo, Sussman, Sarah M., Mediero, Aranzazu, Leucht, Philipp, Jacobson, Kenneth A., Cronstein, Bruce N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733060/
https://www.ncbi.nlm.nih.gov/pubmed/36494860
http://dx.doi.org/10.1186/s13075-022-02961-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733060/
https://www.ncbi.nlm.nih.gov/pubmed/36494860
http://dx.doi.org/10.1186/s13075-022-02961-0

Ejemplares similares